NDAINTRAVESICALSOLUTION
Approved
Apr 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
RIMSO-50 (dimethyl sulfoxide) by Viatris is pharmacology fluocinolone acetonide is chemically related to prednisolone and possesses marked anti-inflammatory properties when applied topically. First approved in 1978.
Drug data last refreshed 18h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIMSO-50 is a dimethyl sulfoxide (DMSO) solution administered intravesically for interstitial cystitis and related bladder conditions. DMSO works through anti-inflammatory mechanisms and enhances penetration of therapeutic agents across the bladder epithelium. It represents a unique small-molecule approach to reducing bladder inflammation and associated urinary symptoms.
$0.591MPart D
LOE ApproachingProduct is approaching loss of exclusivity with minimal Part D spending, signaling small commercial footprint and likely lean brand team structure.
Mechanism of Action
PHARMACOLOGY Fluocinolone acetonide is chemically related to prednisolone and possesses marked anti-inflammatory properties when applied topically. It has been shown to have over 100 times the anti-inflammatory activity of hydrocortisone. Fluocinolone acetonide decreases edema, inflammation,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RIMSO-50 offers experience in a legacy product lifecycle, niche-market sales execution, and specialized bladder disease management. This role is best suited for professionals seeking deep expertise in a focused therapeutic area rather than rapid career scaling or launch experience.
Worked on RIMSO-50 at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.